Synopsis

We endeavored to investigate outcomes associated with use of multiple neurostimulation modalities as compared with conventional SCS settings alone in a prospective, randomized controlled trial. The primary endpoint was proportion of subjects permanently implanted with an SCS system capable of multiple neurostimulation modalities demonstrating 50% or greater reduction in average overall pain intensity at 3-months post-randomization. The study met its primary endpoint based on a pre-specified cohort of 89 randomized subjects (p<0.001). The results provide further support for the advantages of using neuromodulation systems capable of patient-specific stimulation options that enable highly customized therapy for treatment of chronic pain.

Disclosures

Drs. Wallace, North, Washabaugh, Lee, Phillips, and Trainor have consulting agreements with Boston Scientific.
Lilly Chen and Roshini Jain are employees of Boston Scientific.

Mark Wallace MD

University of California, San Diego

Appearances